Sera Prognostics, Inc. announced the acceptance of the findings of the PRIME study for publication in a peer-reviewed journal.
The PRIME study focuses on improving maternal and neonatal health through innovative pregnancy biomarker information.
The study's abstract data was previously presented at the Society for Maternal-Fetal Medicine's annual meeting.
PRIME Study Acceptance
The PRIME study, focused on preterm birth, has been accepted for publication in a medical journal.
PreTRM® Test
Sera Prognostics offers the only broadly validated blood-based biomarker test for early risk prediction of spontaneous preterm birth.
Company Focus
Sera Prognostics is dedicated to precision pregnancy care, aiming to improve the lives of women and babies.
- The acceptance of the PRIME study for publication highlights Sera Prognostics' commitment to advancing maternal and neonatal health.
- The PreTRM Test's unique ability to predict spontaneous preterm birth early in pregnancy provides healthcare professionals with valuable information for personalized care.
Sera Prognostics' success in the PRIME study publication reinforces its position as a leader in pregnancy care innovation.